We are live on ! Find out more
TRPX

Therapix Biosciences Ltd.
TRPX

Delisted

TRPX was delisted on the 1st of July, 2020.

Back to rankings

0 hedge funds and large institutions have $0 invested in Therapix Biosciences Ltd. in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 7 → 0 (-7)

100% less capital invested

Capital invested by funds: $312K → $0 (-$312K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 7

Holders
–
Holders Change
-7
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$271K
2
UBS Group
UBS Group
Switzerland
-$26K
3
Millennium Management
Millennium Management
New York
-$9K
4
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
– -$271K -436,189 Closed
UBS Group
2
UBS Group
Switzerland
– -$26K -41,428 Closed
Millennium Management
3
Millennium Management
New York
– -$9K -14,200 Closed
Envestnet Asset Management
4
Envestnet Asset Management
Illinois
– -$6K -10,018 Closed

TRPX Hedge Fund Activity: Q3 2020 in Review

0 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Therapix Biosciences Ltd. (TRPX) for Q3 2020, worth a combined $0 — down 100% from $312K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of TRPX and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Morgan Stanley, exiting entirely with an estimated $271K sold.

  • 0 institutional investors held Therapix Biosciences Ltd. (TRPX) as of Q3 2020, down from 7 in Q2 2020.
  • Funds reported $0 of Therapix Biosciences Ltd. stock for Q3 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Therapix Biosciences Ltd. positions in Q3 2020 and 7 closed out, a net change of -7 holders.
  • The largest Therapix Biosciences Ltd. seller in Q3 2020 was Morgan Stanley, an estimated $271K sold.

Based on aggregated 13F filings for Q3 2020.